See results of a survey of people who tube feed conducted by Alcresta and the Oley Foundation

Getting started

RELiZORB (immobilized lipase) cartridge

You’ve been prescribed RELiZORB

RELiZORB is used with tube feeding to help break down the fats in your enteral nutrition to a more absorbable form

Your prescription for RELiZORB can only be filled through a specialty pharmacy. Your doctor has submitted your prescription to RELiZORB Support Services (RSS). In order to help with insurance approval coordination, review of anticipated out-of-pocket costs, and setup of RELiZORB delivery, authorization is needed. Please use the links below to start the process.

Are you authorizing for yourself?
Complete this authorization form

Is a representative authorizing on your behalf?
Complete this authorization form

RELiZORB Support Services is a support program committed to helping patients who have been prescribed RELiZORB with product education, insurance assistance, and financial support. Ensure your experience with RELiZORB is the best it can be—connect one-on-one with a dedicated RELiZORB Support Services case manager by calling 1-844-632-9271 or emailing [email protected].

Your dedicated RELiZORB case manager can help with:

Understanding how to use RELiZORB
Insurance assistance
Ordering and delivery of RELiZORB
Out-of-Pocket Assistance Program (for eligible US patients)

Support is just a phone call away at 1-844-632-9271, or email [email protected]

The RELiZORB Support Services team is made up of highly skilled individuals, including a:

Pediatric Nurse Practitioner
Pediatric Occupational Therapist, MBA, MPH
Pediatric Intensive Care Unit Registered Nurse
Pediatric Respiratory Therapist

See how Trenton and his family were supported through every step of their RELiZORB journey.

RELiZORB is indicated for use in pediatric (including neonates and infants) and adult patients to hydrolyze fats during enteral feeding.

Warnings

RELiZORB is for use with enteral tube feeding only.

RELiZORB is indicated for use in pediatric (including neonates and infants) and adult patients to hydrolyze fats during enteral feeding.

Warnings

RELiZORB is for use with enteral tube feeding only.
RELiZORB should not be connected to any intravenous (IV) line, setup, or system.
Medications should not be administered through the RELiZORB cartridge. Do not add medications to the enteral nutrition or tubing before RELiZORB. The passage of medications through RELiZORB may adversely affect the medications or the ability of RELiZORB to hydrolyze fats.
Fibrosing Colonopathy - Fibrosing colonopathy is a rare, serious adverse reaction associated with high-dose use of pancreatic enzyme replacement therapy in the treatment of patients with cystic fibrosis. The underlying mechanism of fibrosing colonopathy remains unknown. Patients with fibrosing colonopathy should be closely monitored because some patients may be at risk of progressing to stricture formation. RELiZORB contains lipase enzyme that is not from a porcine source. The lipase is bound to the beads, and this lipase-bead complex (iLipase) is retained within the RELiZORB cartridge. Continue to follow your physician’s guidance and porcine pancreatic enzyme labeling regarding porcine pancreatic enzyme use when used in conjunction with RELiZORB.

Cautions and Precautions

Do not re-use RELiZORB. RELiZORB is a single-use product. Re-use may result in contamination of the product. If re-used, RELiZORB may not effectively hydrolyze fats.
Do not break, alter, or place excess pressure on any part of RELiZORB. Any compromise of the structural integrity of RELiZORB may lead to improper connection to enteral feeding supplies, leakage or risk of contamination.
Do not use RELiZORB after the date marked on the pouch.
Enteral nutrition administered through RELiZORB is for immediate consumption through an enteral feeding tube. RELiZORB should not be used to process enteral nutrition for later use. This has not been tested and may result in safety issues.
RELiZORB is designed for use with enteral feeding pump systems with low flow/no flow alarms and enteral syringes for manual bolus by syringe (push or gravity). A detailed listing of enteral nutrition, pumps, and enteral feeding supplies compatible with RELiZORB can be found at www.relizorb.com/compatibility.
Patients less than 1 year old may be particularly vulnerable to unplanned interruptions of feeding.
Do not use blenderized formulas with RELiZORB. A detailed listing of enteral nutrition compatible with RELiZORB can be found at www.relizorb.com/compatibility.
Powdered formulas should be mixed periodically during feedings.
Do not use excessive force on the plunger when using RELiZORB with bolus syringe feeding method.
Do not rush bolus feeds. Follow guidance from your healthcare professional on how long it should take you to complete your tube feeding. Ensure all inlet and outlet connectors on RELiZORB and enteral feeding supplies are clean and dry prior to making connections.
In order to ensure product performance, store RELiZORB in its pouch either refrigerated or at room temperature (2°C to 27°C; 36°F to 80°F).
RELiZORB is indicated for use with enteral feeding only; patients should follow physician’s guidance for pancreatic enzyme replacement therapy (PERT) use for meals and snacks. Patients and patient caregivers should follow physician’s guidance regarding the need for pancreatic enzyme replacement therapy (PERT) during enteral feeding.

Review full product information for RELiZORB in the Instructions for Use.